Skip to main content
NCBI home page
CMAJ : Canadian Medical Association Journal logoLink to CMAJ : Canadian Medical Association Journal
. 1996 Oct 1;155(7):945–948.

Prevention and management of osteoporosis: consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. 6. Use of bisphosphonates in the treatment of osteoporosis.

A Hodsman 1, J Adachi 1, W Olszynski 1
PMCID: PMC1335459  PMID: 8837544

Abstract

OBJECTIVE: To describe the mechanisms of action of bisphosphonates in the treatment of osteoporosis and compare bisphosphonate therapy with other treatments. OPTIONS: The bisphosphonates, etidronate, alendronate, clodronate, pamidronate, tiludronate, ibandronate and risedronate; combined bisphosphonates and estrogen; combined bisphosphonates and calcium supplements. OUTCOMES: Fracture and loss of bone mineral density in osteoporosis; increased bone mass, prevention of fractures and improved quality of life associated with bisphosphonate treatment. EVIDENCE: Relevant clinical studies and reports were examined with emphasis on recent controlled trials. The availability of treatment products in Canada was also considered. VALUES: Reducing fractures, increasing bone mineral density and minimizing side effects of treatment were given a high value. BENEFITS, HARMS AND COSTS: Treatment with bisphosphonates may be an acceptable alternative to ovarian hormone therapy in increasing bone mass and decreasing fractures associated with osteoporosis. Compared with estrogens, bisphosphonates are bone-tissue specific, have equal or greater antiresorptive effect and have few side effects and no known risk for carcinogenesis. They also hold promise in treating male osteoporosis and steroid-induced bone loss. Prolonged, continuous treatment with etidronate may lead to impaired calcification of newly formed bone; therefore, etidronate is administered cyclically. This risk is not present in newer generations of bisphosphonates. RECOMMENDATIONS: Bisphosphonate therapies may be considered as an alternative to ovarian hormone therapy in postmenopausal osteopenic or osteoporotic women who cannot or will not tolerate ovarian hormone therapy. They should also be considered in treating male osteoporosis and steroid-induced bone loss. Combination therapy with estrogen may be effective, although more research is needed. Combination therapy with calcium supplements is recommended. Bisphosphonate therapies should be restricted to postmenopausal patients with osteopenia or established osteoporosis and are not yet recommended for younger perimenopausal women as prophylaxis.

Full text

PDF
945

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adachi J., Cranney A., Goldsmith C. H., Bensen W. G., Bianchi F., Cividino A., Craig G. L., Kaminska E., Sebaldt R. J., Papaioannou A. Intermittent cyclic therapy with etidronate in the prevention of corticosteroid induced bone loss. J Rheumatol. 1994 Oct;21(10):1922–1926. [PubMed] [Google Scholar]
  2. Adinoff A. D., Hollister J. R. Steroid-induced fractures and bone loss in patients with asthma. N Engl J Med. 1983 Aug 4;309(5):265–268. doi: 10.1056/NEJM198308043090502. [DOI] [PubMed] [Google Scholar]
  3. Ali N. J., Capewell S., Ward M. J. Bone turnover during high dose inhaled corticosteroid treatment. Thorax. 1991 Mar;46(3):160–164. doi: 10.1136/thx.46.3.160. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Baylink D. J. Glucocorticoid-induced osteoporosis. N Engl J Med. 1983 Aug 4;309(5):306–308. doi: 10.1056/NEJM198308043090509. [DOI] [PubMed] [Google Scholar]
  5. Chesnut C. H., 3rd, McClung M. R., Ensrud K. E., Bell N. H., Genant H. K., Harris S. T., Singer F. R., Stock J. L., Yood R. A., Delmas P. D. Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling. Am J Med. 1995 Aug;99(2):144–152. doi: 10.1016/s0002-9343(99)80134-x. [DOI] [PubMed] [Google Scholar]
  6. Dempster D. W. Bone histomorphometry in glucocorticoid-induced osteoporosis. J Bone Miner Res. 1989 Apr;4(2):137–141. doi: 10.1002/jbmr.5650040202. [DOI] [PubMed] [Google Scholar]
  7. Diamond T., McGuigan L., Barbagallo S., Bryant C. Cyclical etidronate plus ergocalciferol prevents glucocorticoid-induced bone loss in postmenopausal women. Am J Med. 1995 May;98(5):459–463. doi: 10.1016/S0002-9343(99)80345-3. [DOI] [PubMed] [Google Scholar]
  8. Giannini S., D'Angelo A., Malvasi L., Castrignano R., Pati T., Tronca R., Liberto L., Nobile M., Crepaldi G. Effects of one-year cyclical treatment with clodronate on postmenopausal bone loss. Bone. 1993 Mar-Apr;14(2):137–141. doi: 10.1016/8756-3282(93)90240-b. [DOI] [PubMed] [Google Scholar]
  9. Guyatt G. H., Webber C. E., Mewa A. A., Sackett D. L. Determining causation--a case study: adrenocorticosteroids and osteoporosis. Should the fear of inducing clinically important osteoporosis influence the decision to prescribe adrenocorticosteroids? J Chronic Dis. 1984;37(5):343–352. doi: 10.1016/0021-9681(84)90100-0. [DOI] [PubMed] [Google Scholar]
  10. Hanania N. A., Chapman K. R., Kesten S. Adverse effects of inhaled corticosteroids. Am J Med. 1995 Feb;98(2):196–208. doi: 10.1016/S0002-9343(99)80404-5. [DOI] [PubMed] [Google Scholar]
  11. Hodsman A. B. Effects of cyclical therapy for osteoporosis using an oral regimen of inorganic phosphate and sodium etidronate: a clinical and bone histomorphometric study. Bone Miner. 1989 Jan;5(2):201–212. doi: 10.1016/0169-6009(89)90097-4. [DOI] [PubMed] [Google Scholar]
  12. Kanis J. A., McCloskey E. V., Sirtori P., Khan S., Fern D., Eyres K., Aaron J., Beneton M. N. Rationale for the use of clodronate in osteoporosis. Osteoporos Int. 1993;3 (Suppl 2):S23–S28. doi: 10.1007/BF01623223. [DOI] [PubMed] [Google Scholar]
  13. Liberman U. A., Weiss S. R., Bröll J., Minne H. W., Quan H., Bell N. H., Rodriguez-Portales J., Downs R. W., Jr, Dequeker J., Favus M. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med. 1995 Nov 30;333(22):1437–1443. doi: 10.1056/NEJM199511303332201. [DOI] [PubMed] [Google Scholar]
  14. LoCascio V., Bonucci E., Imbimbo B., Ballanti P., Adami S., Milani S., Tartarotti D., DellaRocca C. Bone loss in response to long-term glucocorticoid therapy. Bone Miner. 1990 Jan;8(1):39–51. doi: 10.1016/0169-6009(91)90139-q. [DOI] [PubMed] [Google Scholar]
  15. Lufkin E. G., Wahner H. W., Bergstralh E. J. Reversibility of steroid-induced osteoporosis. Am J Med. 1988 Dec;85(6):887–888. doi: 10.1016/s0002-9343(88)80048-2. [DOI] [PubMed] [Google Scholar]
  16. Lukert B. P., Raisz L. G. Glucocorticoid-induced osteoporosis: pathogenesis and management. Ann Intern Med. 1990 Mar 1;112(5):352–364. doi: 10.7326/0003-4819-112-5-352. [DOI] [PubMed] [Google Scholar]
  17. Meunier P. J. Is steroid-induced osteoporosis preventable? N Engl J Med. 1993 Jun 17;328(24):1781–1782. doi: 10.1056/NEJM199306173282411. [DOI] [PubMed] [Google Scholar]
  18. Miller P. D., Neal B. J., McIntyre D. O., Yanover M. J., Anger M. S., Kowalski L. Effect of cyclical therapy with phosphorus and etidronate on axial bone mineral density in postmenopausal osteoporotic women. Osteoporos Int. 1991 Jun;1(3):171–176. doi: 10.1007/BF01625449. [DOI] [PubMed] [Google Scholar]
  19. Pacifici R., McMurtry C., Vered I., Rupich R., Avioli L. V. Coherence therapy does not prevent axial bone loss in osteoporotic women: a preliminary comparative study. J Clin Endocrinol Metab. 1988 Apr;66(4):747–753. doi: 10.1210/jcem-66-4-747. [DOI] [PubMed] [Google Scholar]
  20. Puolijoki H., Liippo K., Herrala J., Salmi J., Tala E. Inhaled beclomethasone decreases serum osteocalcin in postmenopausal asthmatic women. Bone. 1992;13(4):285–288. doi: 10.1016/8756-3282(92)90072-5. [DOI] [PubMed] [Google Scholar]
  21. Reginster J. Y., Lecart M. P., Deroisy R., Sarlet N., Denis D., Ethgen D., Collette J., Franchimont P. Prevention of postmenopausal bone loss by tiludronate. Lancet. 1989 Dec 23;2(8678-8679):1469–1471. doi: 10.1016/s0140-6736(89)92927-9. [DOI] [PubMed] [Google Scholar]
  22. Reid I. R., King A. R., Alexander C. J., Ibbertson H. K. Prevention of steroid-induced osteoporosis with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD). Lancet. 1988 Jan 23;1(8578):143–146. doi: 10.1016/s0140-6736(88)92721-3. [DOI] [PubMed] [Google Scholar]
  23. Reid I. R. Steroid osteoporosis. Calcif Tissue Int. 1989 Aug;45(2):63–67. doi: 10.1007/BF02561402. [DOI] [PubMed] [Google Scholar]
  24. Skingle S. J., Crisp A. J. Increased bone density in patients on steroids with etidronate. Lancet. 1994 Aug 20;344(8921):543–544. doi: 10.1016/s0140-6736(94)91932-1. [DOI] [PubMed] [Google Scholar]
  25. Storm T., Thamsborg G., Steiniche T., Genant H. K., Sørensen O. H. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med. 1990 May 3;322(18):1265–1271. doi: 10.1056/NEJM199005033221803. [DOI] [PubMed] [Google Scholar]
  26. Struys A., Snelder A. A., Mulder H. Cyclical etidronate reverses bone loss of the spine and proximal femur in patients with established corticosteroid-induced osteoporosis. Am J Med. 1995 Sep;99(3):235–242. doi: 10.1016/s0002-9343(99)80154-5. [DOI] [PubMed] [Google Scholar]
  27. Teelucksingh S., Padfield P. L., Tibi L., Gough K. J., Holt P. R. Inhaled corticosteroids, bone formation, and osteocalcin. Lancet. 1991 Jul 6;338(8758):60–61. doi: 10.1016/0140-6736(91)90058-w. [DOI] [PubMed] [Google Scholar]
  28. Toogood J. H. Complications of topical steroid therapy for asthma. Am Rev Respir Dis. 1990 Feb;141(2 Pt 2):S89–S96. [PubMed] [Google Scholar]
  29. Watts N. B., Harris S. T., Genant H. K., Wasnich R. D., Miller P. D., Jackson R. D., Licata A. A., Ross P., Woodson G. C., 3rd, Yanover M. J. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med. 1990 Jul 12;323(2):73–79. doi: 10.1056/NEJM199007123230201. [DOI] [PubMed] [Google Scholar]
  30. Wimalawansa S. J. Combined therapy with estrogen and etidronate has an additive effect on bone mineral density in the hip and vertebrae: four-year randomized study. Am J Med. 1995 Jul;99(1):36–42. doi: 10.1016/s0002-9343(99)80102-8. [DOI] [PubMed] [Google Scholar]

Articles from CMAJ: Canadian Medical Association Journal are provided here courtesy of Canadian Medical Association

RESOURCES